AOL co-founder Steve Case will be the inaugural speaker for Anchor Ventures’s speaker series. Anchor Ventures is a collaboration between University of Maryland Ventures and Johns Hopkins Technology Ventures.
Paragon Bioservices, the leading private equity-backed biologics contract development and manufacturing organization with proven expertise in gene therapy and next-generation vaccines, is expanding a new process development and cGMP manufacturing facility located conveniently near Baltimore/Washington International Thurgood Marshall (BWI) Airport in Baltimore, Maryland.
2017 marked continued growth for Rockville Economic Development, Inc. (REDI) and the Maryland Women’s Business Center (MWBC).
We are pleased to highlight our many accomplishments in the 2017 Annual Report, which was released today.
Cambridge’s up and coming life sciences firms will be able to benefit from the expertise of some of the biggest names in the sector at a new bio-incubator and life science accelerator.
The pharmaceutical industry continues to pursue the discovery of medicines for cancer patients with unprecedented rigor. Over the past several years, three major trends have reflected this pursuit. They include the growth of the industry pipeline of cancer-drug candidates, the evolution of the clinical-trial landscape, and the explosion of available clinical and real-world data
Paragon Bioservices, the leading private equity-backed biologics contract development and manufacturing organization (CDMO) with proven expertise in gene therapy and next-generation vaccines, announces today the promotion of key personnel and the addition of two industry veterans to its leadership team. Specifically, the Company appoints Philip Wills, PhD, as Chief Commercial Officer, John Conner as Chief Manufacturing Officer, and William “Bill” Thomas, Jr., PhD, as Chief Scientific Officer, and hires Randy Henrickson as VP of Manufacturing and Dermot McCaul as VP of Information Technology.
QIAGEN announced that it has received clearance for its ipsogen JAK2 RGQ PCR Kit (ipsogen JAK2 assay) from the U.S. Food and Drug Administration (FDA) for additional use in the diagnosis of all myeloproliferative neoplasms (MPNs), which are a group of cancers in which immature blood cells in the bone marrow do not mature and become healthy blood cells.
On Jan. 22, 2018, Sanofi announce that it has entered into a definitive agreement to acquire all outstanding shares of Bioverativ, the hemophilia and blood disorders-focused spin-off company of Biogen, for $105 per share, or a transaction value of approximately $11.6 billion. The transaction was unanimously approved by the boards of directors of Sanofi and Bioverativ.
Accelerate@Babraham is designed to support the earliest stages of new life-science ventures, by providing easy-access laboratory and office space, (the ‘bio-incubator’) together with supporting programmes of business, science, finance and entrepreneurial mentoring (the ‘accelerator’) provided by strategic partners.
The ETC (Emerging Technology Centers), Baltimore City’s award-winning technology and innovation centers, announces the Accelerate Baltimore (AB) program will run for its seventh consecutive year and applications are now open. The ETC will select six tech startups for the 13-week program set to begin mid-March. The Abell Foundation has awarded ETC $250,000 in funding for this seed accelerator for the third year in a row. Based on the model of last year’s successful program, each of this year’s AB winners will be awarded $25,000 in seed stage funding, while one company will be awarded an additional $100,000 in follow on funding at the end of the program.